BioVie Inc. (BIVI)
2.00
-0.10 (-4.76%)
At close: Jan 14, 2025, 3:59 PM
2.03
1.45%
Pre-market Jan 15, 2025, 07:22 AM EST
undefined% (undefined)
| Bid | 2.03 |
| Market Cap | 36.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.08 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.1 |
| Volume | 541,833 |
| Avg. Volume (20D) | 6,525,745 |
| Open | 2.12 |
| Previous Close | 2.10 |
| Day's Range | 2.00 - 2.16 |
| 52-Week Range | 1.04 - 33.10 |
| Beta | undefined |
About BIVI
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for ...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2020
Employees 14
Stock Exchange NASDAQ
Ticker Symbol BIVI
Website https://bioviepharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BIVI stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 1399.33% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-23.51%
BioVie shares are trading lower after the company ...
Unlock content with
Pro Subscription
2 months ago ·
Source
+27.76%
BioVie shares are trading higher. The company closed its registered direct offering and concurrent private placement.
